Selling the over-the-counter subsidiary Daiichi Sankyo Healthcare to Suntory Holdings (2026)

The lightness, and the weight, that concentration brings

The core of this decision can be read as a re-examination of what it means to keep a business next to the main one merely because it earns. Daiichi Sankyo Healthcare was an excellent subsidiary with high returns and strong brands, but for a company trying to gather its resources into global competition in cancer drugs, over-the-counter medicine was a foreign infrastructure with its own customers, its own sales force and its own distribution. In the sequencing — selling while the business was strong, and to a counterparty with long ties — one can see the intention of entrusting it to whoever would value it most highly. The skill of the separation shows in this: it was let go by choice while it still had value, not after it had begun to hurt.

Concentration, though, is also a choice that folds away one line of retreat in exchange for lightness. The heavier the dependence on two drugs, Enhertu and Datroway, the more sharply results will turn on label expansions and on whether the follow-on candidates succeed. The steady earnings of the over-the-counter business were a cushion that smoothed those swings. Whether the cancer business it has concentrated on can turn out results exceeding the price received for a fine business given away — the rightness of the choice Daiichi Sankyo has made will be measured quietly, over the next several years of growth in its oncology drugs.